SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Julian who wrote (809)2/11/2000 10:41:00 AM
From: Scripts  Read Replies (1) of 1321
 
Unless I'm reading it wrong it is Feb 12 which is tomorrow I believe:

ATLANTA and VANCOUVER, Dec. 9 /CNW/ - A news release issued by CIBA
Vision, the eyecare unit of Novartis AG and QLT PhotoTherapeutics Inc. dated
November 17, 1999 contained a typographical error incorrectly stating that the
FDA is expected to make a final decision regarding the approval of Visudyne
therapy on or before February 2, 2000. The correct date is February 12, 2000.
Under priority review status, the FDA is expected to complete their
review of the August 16 submission within 180 days; or, on or before February
12, 2000.

Visudyne(TM) is a trademark of Novartis AG.

QLT PhotoTherapeutics Inc. contacts: CIBA Vision contacts:
------------------------------------ ---------------------
Elayne Wandler or Tamara Hicks Ann Berry
Corporate Communications Corporate Communications
QLT PhotoTherapeutics Inc. CIBA Vision Corporation
520 West 6th Avenue 11460 Johns Creek Parkway
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News